This information is current as
of June 16, 2017.
RON Receptor Tyrosine Kinase, a Negative
Regulator of Inflammation, Inhibits HIV-1
Transcription in Monocytes/Macrophages
and Is Decreased in Brain Tissue from
Patients with AIDS
Eileen S. Lee, Parisa Kalantari, Shigeki Tsutsui, Alicia Klatt,
Janet Holden, Pamela H. Correll, Christopher Power and
Andrew J. Henderson
References
Subscription
Permissions
Email Alerts
This article cites 81 articles, 43 of which you can access for free at:
http://www.jimmunol.org/content/173/11/6864.full#ref-list-1
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2004 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
J Immunol 2004; 173:6864-6872; ;
doi: 10.4049/jimmunol.173.11.6864
http://www.jimmunol.org/content/173/11/6864
The Journal of Immunology
RON Receptor Tyrosine Kinase, a Negative Regulator of
Inflammation, Inhibits HIV-1 Transcription in
Monocytes/Macrophages and Is Decreased in Brain Tissue
from Patients with AIDS1
Eileen S. Lee,2,3*‡ Parisa Kalantari,2†‡ Shigeki Tsutsui,§ Alicia Klatt,†‡ Janet Holden,¶
Pamela H. Correll,*†‡ Christopher Power,§ and Andrew J. Henderson4*†‡
A
cquired immunodeficiency syndrome is a multifactorial
disease affecting multiple organs, including skin, lung,
lymphoid tissue, and brain (1). The widespread effects of
AIDS are partly due to a general inflammatory response in which
chronic immune activation leads to increased cytokine secretion
and enhanced virus replication. These events result in tissue damage and the manifestation of many AIDS-related pathologies (1). A
dramatic example of how HIV-1 infection directly and indirectly
leads to tissue damage and pathology is HIV-associated dementia
(HAD).5 Twenty percent of late-stage AIDS patients not receiving
antiretroviral therapy develop HAD, and it has been reported that
Graduate Programs in *Biochemistry, Microbiology and Molecular Biology, and
†
Pathobiology, and ‡Department of Veterinary Science, Pennsylvania State University, University Park, PA 16802; Departments of Clinical Neuroscience, Microbiology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada; and
¶
Department of Pathology, St. Paul’s Hospital, Vancouver, British Columbia, Canada
Received for publication March 31, 2004. Accepted for publication October 1, 2004.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1
This work was supported by National Institutes of Health Grant AI46261 (to A.J.H.)
and Tobacco Formula Funds (to A.J.H. and P.H.C.).
2
E.S.L. and P.K. contributed equally to this work.
3
Current address: Department of Molecular and Cell Biology, Immunology Division,
University of California, Berkeley, CA 94720-3200.
4
Address correspondence and reprint requests to Dr. Andrew J. Henderson, Department of Veterinary Science, 115 Henning Building, Pennsylvania State University,
University Park, PA 16802-3500. E-mail address: [email protected]
5
Abbreviations used in this paper: HAD, HIV-associated dementia; LTR, long terminal repeat; Luc, luciferase; MDM, monocyte-derived macrophages; MSP, macrophage-stimulating protein; VSV-G, vesicular stomatitis-glycoprotein; MSCV, murine stem cell virus.
Copyright © 2004 by The American Association of Immunologists, Inc.
upon autopsy up to 80% of HIV-1-infected individuals have evidence of neurological lesions (2, 3). The symptoms of HAD range
from minor changes in memory and cognitive function to more
severe symptoms that include loss of motor skills, seizures, psychiatric disorders, and dementia. Neuropathological features accompanying HAD include infiltration of macrophages, activation
of resident microglia and astrocytes, myelin pallor, and subsequent
neuronal destruction. CNS pathogenesis associated with AIDS is
largely attributed to infection of macrophages and microglia and
their production of inflammatory mediators (4 – 8). Indeed, the best
pathological correlate of HAD is activation macrophages and microglia (9).
Whether through direct or indirect effects of HIV-1 infection,
macrophages produce a variety of factors that cause HAD, including cytokines, chemokines, and adhesion molecules (10,
11). Elevated levels of IL-1␤, IL-6, and TNF-␣ have been detected in brain tissue of AIDS patients, as has increased expression of the TNF-␣ receptor on macrophages and microglia (1,
12, 13). In addition to promoting inflammation, these cytokines
activate HIV-1 transcription, suggesting an autocrine mechanism for HIV-1 replication (14 –19). Furthermore, dysregulated
expression of IFN-␥, IL-4, IL-10, excitatory amino acids, NO,
as well as ␣- and ␤-chemokines have all been observed in the
CNS of AIDS patients (12, 13). The combined effect of these
factors is altered function and survival of microglia cells, endothelium, astrocytes, and neurons, which exacerbates persistent inflammation and tissue destruction (7, 13).
Dysregulation of the cytokine network in AIDS patients implies
that signaling events that normally control cytokine gene expression are disrupted or altered during HIV-1 infection. Signals that
0022-1767/04/$02.00
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
Activation of macrophages and microglia cells after HIV-1 infection and their production of inflammatory mediators contribute
to HIV-associated CNS diseases. The mechanisms that initiate and maintain inflammation after HIV-1 infection in the brain have
not been well studied. Furthermore, it is not understood why in HIV-associated CNS disease, macrophages and microglia are
biased toward inflammation rather than production of mediators that control inflammation. We have focused on the receptor
tyrosine kinase RON, a critical negative regulator of macrophage function and inflammation, to determine whether this receptor
regulates HIV-1 expression. Overexpressing RON in monocytes/macrophages demonstrates that RON inhibits HIV-1 proviral
transcription in part by decreasing the binding activity of NF-␬B to the HIV-1 long terminal repeat. Because macrophages and
microglia cells are a critical reservoir for HIV-1 in the CNS, we examined brain tissues for RON expression and detected RON
in astrocytes, cortical neurons, and monocytoid cells. RON was detected in all control patients who were HIV seronegative (n ⴝ
7), whereas six of nine brain samples obtained from AIDS patients exhibited reduced RON protein. These data suggest that RON
initiates signaling pathways that negatively regulate HIV-1 transcription in monocytes/macrophages and that HIV-1 suppresses
RON function by decreasing protein levels in the brain to assure efficient replication. Furthermore, HIV-1 infection would
compromise the ability of RON to protect against inflammation and consequent CNS damage. The Journal of Immunology, 2004,
173: 6864 – 6872.
The Journal of Immunology
Materials and Methods
Cells and tissues
The U937 promonocytic cell line was cultured in RPMI 1640 medium
supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 0.2 M L-glutamine. The 293T human embryonic kidney cell line
and the CHME3 microglial cell line were grown in DMEM supplemented
with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 0.2 M
L-glutamine. The U87 glioblastoma cell line was cultured in Eagle’s MEM
supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 U/ml
streptomycin, 0.2 M L-glutamine, 0.1 mM nonessential amino acids, and 1
mM sodium pyruvate. A stable U937-RON cell line was generated through
transduction of U937 cells using a vesicular stomatitis virus glycoprotein
(VSV-G) pseudotyped murine stem cell virus (MSCV)-RON retroviral
vector that expresses a neomycin resistance gene (28). Transduced pools of
cells were maintained for 2 wk after selection with 1 mg/ml G418 (SigmaAldrich, St. Louis, MO). In some experiments cells were treated with IL-6,
TNF-␣, and IFN-␥ (R&D Systems, Minneapolis, MN).
Peripheral blood macrophages were isolated from whole blood obtained
from healthy HIV-1-seronegative donors. Mononuclear cells were obtained
by differential centrifugation using a Ficoll/Hypaque gradient (Sigma-Aldrich) as previously described (29). The cells were cultured in RPMI 1640
supplemented with 10% FCS, 100 U/ml penicillin, 100 ␮g/ml streptomycin, and 0.2 M L-glutamine. Monocytes were separated from lymphocytes
by an initial adherence to plastic culture flasks overnight. After removing
nonadherent cells, monocytes were cultured for 5–7 days to mature into
monocyte-derived macrophages (MDM) before infection. Murine resident
peritoneal macrophages were obtained from wild-type and RON⫺/⫺ CD1
mice (26) by peritoneal lavage with 10 ml of RPMI 1640 containing 10%
FCS. Cells were plated at ⬃3.3 ⫻ 105 cells/ml overnight, then washed with
PBS to eliminate nonadherent cells. Murine macrophages were maintained
in RPMI 1640 plus 10% FBS at 37°C in a humidified incubator containing
5% CO2.
The brain tissues used in these experiments have been described in previous reports (30, 31) and were obtained from the AIDS Brain Bank at St.
Paul’s Hospital (Vancouver, Canada) and the Neurovirology Laboratory
Brain Bank at the University of Calgary. Samples represented frontal white
matter that was collected at autopsy from all experimental groups and
stored at ⫺80°C. The presence of CNS opportunistic infections was excluded by postmortem histopathologic evaluation of brain tissue sections
from adjacent tissue. Control tissues were collected from subjects with a
mean age 56 ⫾ 14 yr who were seronegative for HIV; they included three
normal brains, two brains from stroke patients, one brain from a patient
with endocarditis, and one brain from a patient with anoxic encephalopathy. All HIV-infected patients died of AIDS-related illnesses (mean age,
39 ⫾ 15 year) and had CD4⫹ T cell counts ⬍200/mm3. The HIV-infected
samples were obtained from patients with HIV encephalitis (n ⫽ 3), multifocal leukoencephalitis (n ⫽ 2), toxoplasma encephalitis (n ⫽ 1), microglia nodules (n ⫽ 2), and CMV encephalitis (n ⫽ 1). Neuropsychological
and neurological information was not available for the HIV-infected patients from whom tissues were collected (29, 30). Fetal brain tissues were
provided by Drs. B. Wigdahl (Drexel University, Philadelphia, PA) and R.
Frisque (Pennsylvania State University, University Park, PA). Astrocytes
were provided by Dr. D. Volsky (Columbia University, New York, NY).
Plasmids and transient transfections
293T cells were transiently transfected using CaPO4 (32). The pCI-RON
construct was generated by subcloning the XhoI and NotI 4.5-kb RON
fragment from the pvuless-hRON (provided by Dr. R. Breathnach, Institut
de Biologie, Nantes, France) into the XhoI-NotI sites of pCI-neo vector
(Promega, Madison, WI). An XhoI-EcoRI hRON fragment was subcloned
into the XhoI and EcoRI sites of MSCV2.2 for MSCV-RON. Long terminal
repeat (LTR) reporter constructs LTR-Luc, ⫺158 LTR-Luc, and NF-␬BLuc and pSV2-LUC were previously described (33). DNA for transfections
was prepared using plasmid purification systems from Marligen Biosciences (Ijamsville, MD) following protocols provided by the manufacturer. MFG-GFP was used to control for transfection efficiency and was
assayed 12 h post-transfection by fluorescent microscopy or flow cytometry. RON overexpression did not influence the transfection efficiencies of
the different cell lines (data not shown).
HIV-1 Infections
Replication-deficient virus was generated by transfecting 293T cells with
15 ␮g of pNL43-Luc⫹Env⫺ DNA (34), 3 ␮g of VSV-G-Env DNA, and 3
␮g of Tat by CaPO4 transfection. HXB.2 or HXBnPLAP (35) (HIV-PLAP;
obtained from the AIDS Research Reference Reagent Program, National
Institutes of Health) replication competent virus was generated similarly by
cotransfecting proviral cDNA, and Rev expression constructs. Transfection
efficiency was assessed by luciferase (Luc) activity or p24 levels. We consistently generated titers of 1.0 ⫻ 106 infectious particles/ml. One milliliter
of undiluted viral stocks was added to 1.0 ⫻ 106 cells for 24 h, and the
spent medium was replaced. Cells were harvested 48 h postinfection and
assayed for viral transcription by Luc assays. Cells (1.0 ⫻ 106) were lysed
in 1⫻ Reporter Lysis Buffer (Promega), and supernatants were collected.
Twenty microliters of cell extract was added to 100 ␮l of Luc substrate
(Promega), and activity was measured using a luminometer. In addition,
virus replication was assessed by p24 ELISA (PerkinElmer,
Wellesley, MA).
Nuclear extract preparations and EMSAs
Nuclear extracts were prepared as described previously (36) by lysing
2.0 ⫻ 106 cells with 10% Nonidet P-40 in buffer A (10 mM HEPES (pH
7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 0.5 mM
PMSF). The extracts were recovered in 50 ␮l of buffer C (20 mM HEPES (pH
7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF).
Fifty nanograms of annealed ⫺161 to ⫺94 HIV-1 LTR binding site DNA
(5⬘-GATCGCCCGAGAGCGCATCCGGAGTACTTCAAGAACTGCTGAC
ATCGA-3⬘ and 5⬘-GATCGCGGAAAGTCCCTTGTAGCAAGCTCGATGT
CAGCAGTTCTTGAAG-3⬘) or C/EBP binding site DNA (5⬘-GATCGC
CTAGCATTTCATCACACGT-3⬘ and 5⬘-GATCACGTGTGATGAAATGC
TAGGC-3⬘) was end-filled with [␣-32P]dCTP using bacterial Klenow
fragment (Promega). The DNA probe was used at a specific activity of
108–109 cpm/␮g and incubated with 5 ␮g of nuclear extract samples in a
reaction mixture of a final volume 20 ␮l containing 3 ␮g of dI-dC (Amersham
Biosciences, Arlington Heights, IL), 0.25 M HEPES (pH 7.5), 0.6 M KCl, 50
mM MgCl2, 1 mM EDTA, 7.5 mM DTT, and 9% glycerol for 20 min at 25°C.
A 50-fold excess of unlabeled NF-␬B, C/EBP, or Sp1 binding site DNA was
used as the specific and nonspecific competitors. Anti-NF-␬B p65 Ab (0.5 ␮g;
Santa Cruz Biotechnology, Santa Cruz, CA) was used to supershift complexes.
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
inhibit proinflammatory responses by macrophages have the
potential to inhibit HIV-1 transcription, whereas disrupting these
signals during the course of HIV-1 infection could contribute to a
microenvironment that favors HIV-1 replication and inflammation.
However, whether HIV-1 actually targets receptors that upon engagement inhibit inflammatory function and promote activities that
prevent tissue damage and resolve inflammation has not been thoroughly examined. The receptor tyrosine kinase, RON, has recently
been shown to be a critical regulator of macrophage function and
inflammation (20). RON, a member of the MET family of receptor
tyrosine kinases, regulates a variety of cellular responses, including proliferation, differentiation, apoptosis, and cell movement
(20). The ligand for RON is macrophage-stimulating protein
(MSP), a serum protein sharing high homology with the MET
ligand, hepatocyte growth factor. Activation of RON by MSP inhibits the production of proinflammatory mediators such as IL-12,
TNF-␣, and NO (21–23) and induces the expression of genes associated with resolving inflammation, including scavenger receptor A, IL-1Ra, and arginase (24). RON activation also promotes
CR3-mediated phagocytosis and ICAM-1-dependent adhesion of
macrophages (25). Macrophages from RON knockout mice produce elevated levels of NO in response to IFN-␥ and LPS and
exhibit increased inflammation, tissue damage, and death due to
endotoxic shock upon LPS challenge (26). RON knockout mice
also have compromised cell-mediated immunity, as demonstrated
by an increased susceptibility to Listeria monocytogenes infection
(27).
Because HIV-1 transcription is tightly linked to proinflammatory signals, the suppression of this response might be predicted to
inhibit virus expression. We directly tested whether the antiinflammatory signals initiated by RON could inhibit HIV-1 transcription. We demonstrate that RON inhibits HIV-1 transcription
in part by targeting NF-␬B activation. Furthermore, we show that
RON protein is consistently decreased in brain tissue from AIDS
patients, suggesting that chronic HIV-1 infection results in the
down-regulation of this receptor tyrosine kinase.
6865
6866
RON RECEPTOR TYROSINE KINASE INHIBITS HIV-1 TRANSCRIPTION
The samples were run on a 6% polyacrylamide gel and visualized by
autoradiography.
RNA extraction and RT-PCR
Total cellular RNA was prepared by lysing cells with 4 M guanidinium
thiocyanate, 25 mM sodium citrate (pH 7), 0.5% sarkosyl, and 0.1 M
2-ME, followed by phenol-chloroform extraction (37). cDNA was prepared from 2 ␮g of cellular RNA using murine leukemia virus reverse
transcriptase and random primers. To amplify the cDNA, a 30-cycle PCR
of 94°C for 1 min, 55°C for 2 min, and 72°C for 3 min was performed with
0.2 ␮g of cDNA using various primers. RON cDNA was amplified using
the upstream primer 5⬘-TAGCAGTGCAACCCCTCTTT-3⬘ and the downstream primer 5⬘-GTAAAGCCAGCAGCTCCATC-3⬘. ␤-Actin cDNA
was amplified using the upstream primer 5⬘-CCTAAGGCCAACCGT
GAAAAG-3⬘ and the downstream primer 5⬘-TCTTCATGGTGCTAG
GAGCCA-3⬘.
Immunoblotting
Immunohistochemistry
Human brain tissues were embedded in paraffin and sectioned into 5-␮m
samples. After removal of paraffin and hydration with decreasing concentrations of ethanol, sections were boiled in 0.01 M citrate buffer in preparation for staining. To block endogenous peroxidases, samples were incubated in 0.3% H2O2. Sections were blocked with 10% normal goat
serum/0.5% Triton X-100 before adding primary Abs diluted in PBS supplemented with 10% normal goat serum. Primary Abs included rabbit-antiRON polyclonal Ab and anti-CD45 (DakoCytomation, Carpinteria, CA),
whereas controls were isotype-matched IgG. Primary Abs were detected
with biotinylated goat anti-rabbit or biotinylated goat anti-mouse Abs, followed by avidin-biotin-peroxidase complexes. Peroxidase activity was detected by diaminobenzidine or alkaline phosphatase (Vector Laboratories,
Burlingame, CA), as previously reported (31). Hematoxylin was used to
counterstain sections to assist in identifying cells expressing RON.
Results
RON receptor tyrosine kinase inhibits HIV-1 transcription
RON has been shown to play a key regulatory role during macrophage activation. Because HIV-1 transcription in macrophages is
associated with inflammation, we posited that RON would suppress HIV-1 transcription. To investigate the ability of RON to
influence HIV-1 LTR activity, 293T cells were transiently transfected with an LTR-Luc reporter construct (33) in the absence or
the presence of RON. LTR activity was assessed by measuring Luc
activity. As shown in Fig. 1A, the presence of RON inhibited LTR
activity by 3-fold compared with LTR-Luc transfected in the absence of RON. This response is specific to the HIV-1 LTR, because SV40 early promoter (pSV2-Luc) activity was comparable
in the absence or the presence of RON (Fig. 1). These data suggest
that the RON receptor tyrosine kinase inhibits HIV-1 transcription.
It should be noted that we observed constitutive signaling when
RON was overexpressed, and addition of MSP had no significant
FIGURE 1. Decreased HIV-1 transcription in the presence of RON. A,
293T cells were transfected with 1 ␮g of LTR-Luc or pSV2-Luc and 1 ␮g
of pCI empty vector or pCI-RON. Cells were harvested 48 h post-transfection and assayed for Luc activity. B, Primary MDM transduced with
MSCV or MSCV-RON were infected with HIV-LUC (1 ⫻ 106 infectious
particles/1 ⫻ 106 cells), and 24 h postinfection cells were harvested to
measure Luc activity. The data in A and B are presented as the percentage
of Luc, with Luc activity in the cells lacking RON being set at 100%. C,
U937 cells transduced with MSCV (MOCK) or MSCV-RON were infected
with HIV-Luc. Twenty-four hours postinfection, cells were cultured in 1%
serum medium for 6 h, then treated with 10 ng/ml IL-6 and 10 ng/ml TNF
for 12 h before performing Luc assays. Data are presented as Luc activity,
and the values shown in the figure are for unstimulated U937-MOCK and
U937-RON cells. f, Data obtained with mock-transfected or transduced
cells; 䡺, data for cells overexpressing RON. For transfections, MFG-GFP
was used to control for transfection efficiency (see Materials and Methods),
and RON overexpression did not influence the transfection efficiencies of
the different cell lines (data not shown). Each data point represents three
independent transfections, and error bars show the SD of these replicates.
Each set of data is representative of at least three experiments.
effect on our results (data not shown). This is consistent with previous studies showing that overexpression of RON leads to constitutive activity of the receptor (21, 38). In addition, the phenotype
of the RON knockout mice, which is a deficiency in resolving
inflammation, is more severe than the modest phenotype observed
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
Cells (5 ⫻ 106) were lysed in 100 ␮l of phosphatase inhibitor lysis buffer
(10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA (pH 8.0), 2 mM
sodium vanadate, 10 mM sodium fluoride, 10 mM sodium pyrophosphate,
1% Nonidet P-40, 1 mM PMSF, and 1 mM pepstatin). An equal volume of
whole cell lysate was added to 2⫻ SDS loading buffer (100 mM Tris-HCl
(pH 6.8), 4% SDS, 0.2% bromophenol blue, 20% glycerol, and 200 mM
DTT) and run on a 6% SDS-polyacrylamide gel. After transfer of proteins
to the nitrocellulose membrane, rabbit-anti-RON polyclonal Ab (Santa
Cruz Biotechnology) was used to probe for RON, or rabbit-anti-I␬B␣ polyclonal Ab (Santa Cruz Biotechnology) was used to detect I␬B␣. HRPconjugated, goat anti-rabbit IgG (Sigma-Aldrich) was used as the secondary Ab. Proteins were detected using the ECL Plus Western blotting
detection system (Amersham Biosciences) and exposure to film. Filters
were stripped 45 min at 55°C using 100 mM ␤-ME, 62.5 mM Tris-HCl (pH
6.7), and 2% SDS and were reprobed with mouse anti-␤-actin (SigmaAldrich), which was detected with HRP-conjugated, goat anti-mouse secondary Ab. For detection of nuclear p65 by immunoblots, 20 ␮g of nuclear
extracts were separated by 6% SDS-PAGE and transferred to nitrocellulose
as described above. Primary staining was performed with rabbit anti-p65
polyclonal Ab (Santa Cruz Biotechnology), and the secondary Ab was
HRP-conjugated, goat anti-rabbit IgG (Sigma-Aldrich).
The Journal of Immunology
FIGURE 3. Ectopic RON expression inhibits HIV-1 replication. A,
U937-mock (solid line) and U937-RON (dashed line) cells were infected
with HXB2 virus (1 ⫻ 106 infectious particles/1 ⫻ 106 cells). Various
times postinfection, supernatants were collected and assayed for viral replication by p24 ELISA. Each data point represents three independent infections, and error bars show the SD of these replicates. These data are
representative of four independent experiments. B, MDM transduced with
MSCV or MSV-RON were infected with HIV-PLAP virus (1 ⫻ 106 infectious particles/1 ⫻ 106 cells), and p24 was measured 8 days postinfection. These data represent at least four independent infections.
endogenously expressed RON was capable of regulating HIV-1
transcription, we infected peritoneal macrophages obtained from
RON wild-type and RON-deficient mice (26) with VSV-G
pseudotyped HIV-LUC. Although HIV-1 does not replicate in
mouse cells, the murine system recapitulates aspects of HIV-1 Tatindependent transcriptional regulation observed in the human cells
(43– 45). As shown in Fig. 4 the RON-deficient cells supported
HIV-1 transcription more efficiently than the wild-type controls.
These data suggest that physiological levels of RON are sufficient
to influence HIV-1 transcription.
RON targets NF-␬B to inhibit HIV-1 transcription
FIGURE 2. RON expression in brain tissue and cell lines. A, mRNA
was extracted from cell lines, primary MDM, and 17-wk fetal human brain
tissue, and RT-PCR was performed for RON expression. B, Whole cell
extracts were prepared from fetal human brain, primary astrocytes, transduced U937 cells, and transduced primary MDM and analyzed for RON
protein expression by immunoblotting with anti-RON Ab.
Signaling through RON potentially alters the activity of cellular
transcription factors necessary for HIV-1 transcription. It has been
demonstrated that RON signaling inhibits NF-␬B activity (21),
which is an important transcriptional activator for HIV-1 (46 – 48).
To determine whether RON is targeting NF-␬B activity to block
HIV-1 transcription, 293T cells were cotransfected with an NF␬B-Luc reporter and a RON expression construct or empty vector
control. A 7-fold decrease in Luc activity was observed in 293T
cells cotransfected with NF-␬B-Luc and RON compared with cells
cotransfected with NF-␬B-Luc and empty vector (Fig. 5A). RON
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
in mice lacking MSP, suggesting that RON has additional uncharacterized ligands or ligand-independent activity (26).
Human monocytic cell lines or primary macrophages that express RON are not readily available because this protein is found
predominantly on tissue resident macrophages (20, 39 – 42). Therefore, to study the effects of RON on HIV-1 expression in relevant
cell types, primary monocyte-derived macrophages were transduced with an MSCV-RON retroviral vector and subsequently infected with a replication defective HIV-1 in which a Luc reporter
gene (HIV-Luc) was inserted into Nef (34); Luc serves as a reporter for proviral transcription. The expression of RON in these
cells was confirmed by RT-PCR and immunoblotting (Fig. 2).
Overexpression of RON in primary macrophages inhibited HIVLuc proviral transcription by ⬎4-fold compared with macrophages
expressing empty MSCV vector (Fig. 1B). To more readily study
the biochemical mechanism by which RON inhibits HIV-1, we
transduced U937 cells with an MSCV-RON retroviral vector to
establish a U937 cell line stably expressing RON (U937-RON).
RON expression was confirmed by RT-PCR and immunoblotting
(Fig. 2). U937-RON cells and U937 cells transduced with the
empty vector (U937-MSCV) were infected with HIV-Luc and assayed for Luc activity. Overexpression of RON in U937 cells inhibited HIV-Luc transcription compared with U937-MSCV controls and dramatically diminished cytokine-induced activation of
HIV-1 transcription in monocytic cells (Fig. 1C). The observed
decrease in HIV-1 transcription is not due to a RON-mediated
block in virus entry, because no difference was seen in proviral
integration as determined by PCR and Southern blot in the U937MSCV and U937-RON cell lines (data not shown).
To determine whether RON could alter HIV-1 replication, U937
and U937-RON cells were infected with HXB2 virus and assayed
for virus replication over 3 wk by p24 ELISA. Three weeks postinfection, a 2- to 4-fold decrease in HIV-1 replication was observed
in cells expressing RON compared with cells not expressing RON
(Fig. 3A). HIV-1 replication was similarly inhibited in MDM that
were transduced with RON (Fig. 3B). Taken together, our data
suggest that RON inhibits HIV-1 transcription and replication.
The above experiments depend on overexpressing RON and
may exaggerate the ability of RON to negatively regulate HIV-1
transcription. However, as mentioned, human cells that express
RON are not readily accessible. Therefore, to determine whether
6867
6868
RON RECEPTOR TYROSINE KINASE INHIBITS HIV-1 TRANSCRIPTION
had no effect on the activity of an NFAT reporter control (data not
shown).
To investigate whether RON affects NF-␬B binding activity,
EMSAs were performed using a probe derived from the HIV-1
LTR spanning nucleotides ⫺161 to ⫺94, which contains sites for
multiple factors, including NF-␬B. U937-RON and U937-MSCV
cells were stimulated with IL-6, TNF-␣, and IFN-␥ to strongly
induce NF-␬B. A decrease in binding activity was observed in
extracts from U937-RON cells compared with U937-MSCV cells
(Fig. 5B). This complex could be competed away with cold NF-␬B
binding site oligonucleotide, but not with nonspecific binding site
competitor and could be supershifted with an anti-p65 Ab. Consistent with this decrease in binding activity, nuclear extracts from
RON-expressing cells had decreased p65 after induction with IL-6,
TNF-␣, and IFN-␥ compared with MSCV-transduced controls, as
determined by immunoblotting (Fig. 5C). Furthermore, I␬B-␣, a
negative regulator of NF-␬B nuclear translocation, was more resistant to degradation after cytokine activation in RON-expressing
cells (Fig. 5D). These data indicate that RON signaling decreases
NF-␬B activation.
Because the HIV-1 LTR contains binding sites for multiple host
factors, we were interested as to whether other transcription factors
might be affected by RON. Besides NF-␬B, another important factor for HIV-1 replication in monocytes/macrophages is C/EBP␤
(33, 49 –51). However, EMSA using labeled C/EBP binding site
oligonucleotides showed equivalent complex formation in both
U937-RON and U937-MSCV cells (Fig. 5E), suggesting that
C/EBP factors are not downstream of RON signaling in monocytic
cells.
RON is expressed in human brain
Given the pivotal role of macrophages and microglia in supporting
HIV-1 replication in the brain and the development of HAD, we
examined the expression of RON in the human brain. RON mRNA
has previously been shown to be expressed in the mouse hippocampus and hypothalamus and in dorsal root ganglia (52, 53),
however, the expression of RON in human brains has not been
examined. We used RT-PCR, immunoblots, and immunohisto-
RON expression is decreased in HIV-associated CNS
inflammatory diseases
RON negatively regulates inflammation; therefore, we would predict that RON expression might be altered during chronic inflammation induced by HIV-1 infection of the brain. We obtained adult
human brain tissues from uninfected control individuals or AIDS
patients (30, 31) and examined them by immunoblotting for RON
protein. Neuropathological evaluation of the samples from AIDS
patients revealed that three patients had HIV encephalitis, and the
remaining cases exhibited other neuropathological features (30,
31). RON was detected in all seven control patients who were HIV
seronegative, whereas six of the nine samples obtained from AIDS
patients, including all three that exhibited encephalitis, had reduced RON expression. A subset of these samples is shown in Fig.
8. These data suggest that HIV-1 may directly or indirectly target
RON to assure a microenvironment that is favorable for virus
replication.
Discussion
HIV-1 infection of macrophages is associated with activation and
elevated expression of inflammatory cytokines, which potentially
feed back in an autocrine fashion to further induce HIV-1 transcription as well as contribute to the tissue destruction and dysregulated growth observed in AIDS-associated diseases of the
brain, skin, lymph nodes, and lung. The mechanisms that contribute to the inappropriate macrophage function are not clear, although it seems likely that HIV-1 specifically targets receptors and
signaling events that negatively regulate inflammation. Critical
regulators of inflammation include Fc␥R, phosphatidylserine receptor, and the Tyro 3 family of receptors (56 –59). HIV-1 has
been associated with a decrease in the expression of Fc␥Rs (60)
and inhibition of Fc-mediated phagocytosis (61). Our data suggest
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
FIGURE 4. HIV-1 transcription is enhanced in RON⫺/⫺ macrophages.
Peritoneal macrophages from wild-type and RON⫺/⫺ CD1 mice were
transduced with HIV-LUC virus pseudotyped with the VSV-G envelope.
Luc activity was measured 48 h postinfection as an indication of proviral
transcription. Comparable levels of provirus were detected in the various
macrophages by PCR of genomic DNA for HIV-1 proviral sequences (data
not shown). Each data point represents three independent infections, and
error bars show the SD of these replicates. These data are representative of
three independent experiments.
chemistry to examine RON expression in human tissues. Seventeen-week gestation human fetal brain tissue was examined for
RON mRNA by RT-PCR. As shown in Fig. 2, RON mRNA was
detected in brain samples, whereas monocytic cell lines and primary MDM did not exhibit RON expression. This is consistent
with previous observations that RON is preferentially expressed on
tissue-resident macrophages (20, 39 – 42). Furthermore, RON protein was detected by immunoblots in samples prepared from human brain tissue as well as primary astrocytes isolated from in
vitro cultures (Fig. 2B). To define which cells express RON, we
examined tissue sections from white matter and cortex, which
showed abundant RON immunoreactivity detected by immunohistochemistry (Fig. 6A). RON was present on ⬃50% of cells that
were immunopositive for CD45 (Fig. 6A), indicating that RON is
expressed in a subset of monocytoid cells within the brain. In
addition, RON immunoreactivity was present on cortical neurons
(data not shown). Fewer RON-immunopositive cells were observed in white matter sections from HIV patients (Fig. 6B) compared with controls. MSP immunoreactivity was also observed in
white matter of both control and HIV patients (Fig. 6C), largely in
CD45-immunopositive cells (Fig. 6C, inset). Taken together, these
data suggest that RON is expressed in monocyte-derived cells
where it potentially regulates inflammatory responses.
To determine whether RON inhibited HIV-1 transcription in the
context of cells derived from the CNS, we cotransfected RON with
HIV-LUC cDNA into brain-derived cell lines: CHME3, a transformed human microglia line (54), and U-87MG, a glioblastoma
(55). RON inhibited HIV-1 transcription by ⬎5-fold in both these
cell types (Fig. 7), suggesting that the signals downstream of RON
that suppress HIV-1 expression are operative in CNS-derived cell
types.
The Journal of Immunology
6869
that RON receptor tyrosine kinase, which has also been shown to
negatively regulate inflammation and macrophage function (20),
inhibits HIV-1 expression and may be a target of HIV-1 infection.
RON signaling has been demonstrated to inhibit the transcription of
iNOS, TNF-␣, and IL-12 (21–23, 62) and, based on our findings,
HIV-1. RON activation has been previously shown to inhibit NF-␬B
activity (21), and our data are consistent with these findings. Because
NF-␬B is critical for efficient HIV-1 transcription in monocytes/macrophages (46, 47, 63), inhibition of NF-␬B would be expected to
compromise HIV-1 LTR activity and proviral transcription. RON
does not lead to a general decrease in transcription factor activity,
because C/EBP binding activity remained unchanged regardless of
RON expression. However, physical and functional interactions between NF-␬B and other factors might be important for the transactivation of the HIV-1 LTR (64, 65).
RON signaling requires two critical tyrosine residues, 1353
and 1360, in the C-terminal domain that serve as multifunctional docking sites for SH2-containing signaling proteins, including Grb2, phospholipase C-␥, Src homology domain 2-containing phosphatase 1, SHIP, and p85, the regulatory subunit of
PI3K (66, 67). RON activates PI3K signaling, and inhibition of
NO production is PI3K-dependent (22, 25). Previous studies
have indicated a role for PI3K in negatively regulating HIV-1
transcription in T cells (68), although whether PI3K inhibits
HIV-1 transcription in macrophages has not been determined.
In addition, there are two tyrosine residues, 1238 and 1239, in
the catalytic domain of RON that are crucial for kinase activity
of the receptor (69), but whether these residues are required for
suppression of HIV-1 transcription has not been investigated.
Other signaling pathways downstream of RON include the
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
FIGURE 5. Inhibition of NF-␬B activity upon RON overexpression. A, 293T cells were transfected with 1 ␮g of NF-␬B-Luc and 1 ␮g of pCI empty
vector or pCI-RON DNA. Cells were harvested 48 h post-transfection and assayed for Luc activity as an indication of transcription. MFG-GFP was used
to control for transfection efficiency as described in Materials and Methods. Error bars are the SD for three independent transfections. These data are
representative of results from three experiments. B–E, U937-mock (MOCK) or U937-RON (RON) extracts were untreated or treated with 10 ng/ml IL-6,
10 ng/ml TNF-␣, and 100 U/ml IFN-␥ (cytokines) for 6 h before preparing nuclear or whole cell extracts. B, EMSA with 4 ␮g of nuclear extracts using
a radiolabeled probe spanning ⫺161 to ⫺94 of the HIV-1 LTR. A 50-fold excess of cold NF-␬B and Sp1 binding site oligonucleotides were used as specific
and nonspecific competitors, respectively. Supershifts were performed using 1 ␮g of anti-p65 Ab. Isotype control Ab did not alter the complex (data not
shown). C, Immunoblots for detection of nuclear p65. Twenty micograms of nuclear extracts were probed with anti-p65 polyclonal Ab. D, Whole cell
extracts from the indicated cells were probed for I␬B␣, stripped, and reprobed for ␤-actin. E, EMSA with 4 ␮g of U937-MSCV or U937-RON nuclear
extracts treated with cytokines for 6 h using a radiolabeled C/EBP binding site. A 50-fold excess of cold C/EBP (COMP) and Sp1 binding site oligonucleotides (NS) were used as competitors.
6870
RON RECEPTOR TYROSINE KINASE INHIBITS HIV-1 TRANSCRIPTION
FIGURE 6. RON and MSP protein expression in human brain. A, RON
immunoreactivity in white matter glia (arrows) from an HIV-seronegative
patient. The inset shows double-label immunoreactivity displaying CD45
(brown) and RON (blue) immunoreactivity on microglia (inset, arrow). B,
RON immunoreactivity in white matter glia (arrow) from an HIV encephalitis patient. C, MSP immunoreactivity was detected in white glia (arrowhead), which were largely CD45-immunopositive (inset).
MAPK pathway and STAT3 activation (20), both of which have
been reported to regulate HIV-1 replication (70 –73).
Gene targeting studies have indicated that RON has a critical
role in mouse development and normal immune function (26, 74).
Macrophages from RON-deficient mice do not properly resolve
inflammation, leading to elevated levels of NO in response to
IFN-␥ and LPS, increased tissue damage, and death due to endotoxic shock (26). Similarly, HIV-1-infected macrophages in the
brain are chronically activated and produce elevated levels of inflammatory cytokines, resulting in destruction of the blood-brain
barrier and surrounding brain tissue (12, 13). This chronic activation of brain macrophages could be in part attributed to a breakdown in pathways required for immune homeostasis in the brain
microenvironment. We propose that in the brain RON is a protective barrier against inflammation, and that HIV-1 infection, either
directly or indirectly, alters RON function, contributing to an inflammatory microenvironment that favors HIV-1 replication. RON
and MSP are expressed in multiple cell types in the CNS (this
study and data not shown) (75, 76), and MSP has been suggested
to act as neurotrophic factor for subsets of sensory and sympathetic
neurons during development (53, 75, 76), although we have not
seen altered MSP expression in brains from HIV patients (data not
shown). However, the consistent decrease in RON protein in AIDS
patients suggests that chronic HIV-1 infection alters RON protein
levels.
It is not clear whether HIV-1 infection directly or indirectly
down-regulates RON expression, although in regions exhibiting
encephalitis, usually representing high levels of HIV replication,
RON immunoreactivity was markedly reduced. We are currently
examining mechanisms by which HIV-1 may directly alter RON
expression and function. HIV-1-encoded proteins such as Nef and
Tat have a myriad of activities that influence gene expression,
signal transduction, receptor turnover, and cell growth and differentiation. Nef interacts with a variety of signal transduction pro-
teins and has been shown to down-regulate surface expression of
CD4, CD28, MHC class I molecules, and Fc␥Rs (77–79). Tat also
has been demonstrated to have several activities, including regulating transcription and cell growth and differentiation (80). Furthermore, cytokine production and inflammatory mediators initiated by HIV-1 infection in the brain (12, 13) could influence RON
expression and function through an autocrine/paracrine mechanism (20, 81). Finally, HIV-1-induced inflammation may lead to
the death of cells that express RON, including neurons and astrocytes, as well as the infiltration and/or expansion of RON-negative
lymphocytes and macrophages within the brain, resulting in an
overall decrease in RON protein in the brain. For example, although our preliminary immunostaining suggest a reduction in the
percentage of cells expressing both RON and CD45 in HIV-infected brain samples, these tissues typically had more CD45⫹ cells
than control brain samples (S. Tsutsui and C. Power, unpublished
observation).
In summary, we have demonstrated that the tyrosine kinase receptor RON, which normally controls inflammatory activities of
macrophages, inhibits HIV-1 transcription. Furthermore, we
present evidence that RON protein is decreased in the brain in a
subset of AIDS patients. These findings imply that HIV-1 infection
FIGURE 8. RON is decreased in AIDS patients with CNS disease.
Brain tissue extracts were prepared from AIDS patients, including two
patients with HIV encephalitis (HIVE) or an uninfected patient (control),
and RON protein was detected by immunoblotting. Filters were stripped
and reprobed for ␤-actin as a loading control. Each tissue sample was
examined for RON expression by immunoblotting at least three times.
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
FIGURE 7. RON inhibits HIV-1 transcription in CNS-derived cell
lines. CHME3 and U-87MG were cotransfected with HIV-LUC cDNA and
pCI-RON (RON) or pCI (MOCK). Twelve hours post-transfection, cells
were assayed for Luc activity. f, Cells that lack RON; 䡺, cells overexpressing RON. Data are presented as the percentage of Luc, with Luc
activity in the cells lacking RON being set at 100%. Error bars are the SD
among three independent transfections. These data represent a single experiment that was performed four times. MFG-GFP was used to control for
transfection efficiency, as described in Materials and Methods.
The Journal of Immunology
compromises immune function in part by disrupting normal signals that actively suppress inflammation and provide unique insights into the progression of diseases such as HAD.
Acknowledgments
We thank Lisa Finkelstein (National Human Genome Research Institute/
National Institutes of Health) for assistance with generating the RON expression constructs, and Margaret Kensinger and Sarah Shelby for technical support. We also thank Dr. Brian Wigdahl (Drexel University,
Philadelphia, PA) for cells from primary glia cultures, and Dr. David Volsky (Columbia University, New York, NY) for purified astrocytes. In addition, the General Clinical Research Center at Pennsylvania State University assisted with blood collection.
References
23. Morrison, A. C., C. B. Wilson, M. Ray, and P. H. Correll. 2004. Macrophagestimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON
receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-␥ and lipopolysaccharide. J. Immunol. 172:1825.
24. Morrison, A. C., and Correll, P. H. 2002. Activation of the stem cell-derived
tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein
results in the induction of arginase activity in murine peritoneal macrophages.
J. Immunol. 168:853.
25. Lutz, M. A., and P. H. Correll. 2003. Activation of CR3-mediated phagocytosis
by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol
3-kinase, and protein kinase C␨. J. Leukocyte Biol. 73:802.
26. Correll, P., A. Iwama, S. Tondat, G. Mayrhofer, T. Suda, and A. Bernstein. 1997.
Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Function 1:69.
27. Lutz, M. A., F. Gervais, A. Bernstein, A. L. Hattel, and P. H. Correll. 2002. STK
receptor tyrosine kinase regulates susceptibility to infection with Listeria monocytogenes. Infect. Immun. 70:416.
28. Bartz, S., and M. Vodicka. 1997. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein.
Methods 12:337.
29. Henderson, A. J., and K. L. Calame. 1997. CCAAT/enhancer binding protein
(C/EBP) sites are required for HIV-1 replication in primary macrophages but not
in CD4⫹ T cells. Proc. Natl. Acad. Sci. USA 94:8714.
30. Johnston, J., C. Silva, J. Holden, K. Warren, A. Clark, and C. Power. 2001.
Monocyte activation and differentiation augment human endogenous retrovirus
expression: implications for inflammatory brain diseases. Ann. Neurol. 50:434.
31. Boven, L. A., N. Vergnolle, S. D. Henry, C. Silva, Y. Imai, J. Holden, K. Warren,
M. D. Hollenberg, and C. Power. 2003. Up-regulation of proteinase-activated
receptor 1 expression in astrocytes during HIV encephalitis. J. Immunol.
170:2638.
32. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of
high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci.
USA 90:8392.
33. Henderson, A. J., X. Zou, and K. L. Calame. 1995. C/EBP proteins activate
transcription from the human immunodeficiency virus type 1 long terminal repeat
in macrophages/monocytes. J. Virol. 69:5337.
34. Connor, R., B. Chen, S. Choe, and N. Landau. 1995. Vpr is required for efficient
replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
Virology 206:936.
35. Chen, B., R. Gandhi, and D. Baltimore. 1996. CD4 down-modulation during
infection of human T cells with human immunodeficiency virus type 1 involves
independent activities of vpu, env, and nef. J. Virol. 70:6044.
36. Screiber, E., P. Matthias, M. M. Muller, and W. Schaffner. 1989. Rapid detection
of octamer binding proteins with miniextracts prepared from a small number of
cells. Nucleic Acids Res. 17:6419.
37. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem.
162:156.
38. Follenzi, A., S. Bakovic, P. Gaul, M. C. Stella, P. Longati, and P. M. Comoglio.
2000. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19:3041.
39. Iwama, A., M. Wang, N. Yamaguchi, N. Ohno, K. Okano, T. Sudo, M. Takeya,
F. Gervais, C. Morissette, and E. Leonard. 1995. Terminal differentiation of murine resident peritoneal macrophages is characterized by expression of the STK
protein tyrosine kinase, a receptor for macrophage stimulating protein. Blood
86:3394.
40. Kurihara, N., A. Iwama, J. Tatsumi, K. Ikeda, and T. Suda. 1996. Macrophage
stimulating protein activates STK receptor tyrosine kinase on osteoclasts and
facilitates bone resorption by osteoclast-like cells. Blood 87:3704.
41. Brunelleschi, S., L. Penengo, L. Lavagno, C. Santoro, D. Colangelo, I. Viano, and
G. Gaudino. 2001. Macrophage stimulating protein (MSP) evokes superoxide
anion production by human macrophages of different origin. Br. J. Pharmacol.
134:1285.
42. Nanney, L., A. Skeel, J. Luan, S. Polis, A. Richmond, M. Wang, and E. Leonard.
1998. Proteolytic cleavage and activation of pro-macrophage stimulating protein
and upregulation of its receptor in tissue injury. J. Invest. Dermatol. 111:573.
43. Kurth, J., J. M. Buzy, L. Lindstrom, and J. E. Clements. 1996. In vivo transcriptional regulation of the human immunodeficiency virus in the central nervous
system in transgenic mice. J. Virol. 70:7686.
44. Dickie, P., R. Gazzinelli, and L. J. Chang. 1996. Models of HIV type 1 proviral
gene expression in wild-type HIV and MLV/HIV transgenic mice. AIDS Res.
Hum. Retroviruses 12:1103.
45. Klotman, P. E., J. Rappaport, P. Ray, J. B. Kopp, R. Franks, L. A. Bruggeman,
and A. L. Notkins. 1995. Transgenic models of HIV-1. AIDS 9:313.
46. Asin, S., G. D. Bren, E. M. Carmona, N. J. Solan, and C. V. Paya. 2001. NF-␬B
cis-acting motifs of the human immunodeficiency virus (HIV) long terminal repeat regulate HIV transcription in human macrophages. J. Virol. 75:11408.
47. Jacque, J. M., B. Fernandez, F. Arenzana-Seisdedos, D. Thomas, F. Baleux,
J. L. Virelizier, and F. Bachelerie. 1996. Permanent occupancy of the human
immunodeficiency virus type 1 enhancer by NF-␬B is needed for persistent viral
replication in monocytes. J. Virol. 70:2930.
48. Griffin, G. E., K. Leung, T. M. Folks, S. Kunkel, and G. J. Nabel. 1989. Activation of HIV gene expression during monocyte differentiation by induction of
NF-␬B. Nature 339:70.
49. Henderson, A. J., R. I. Connor, and K. L. Calame. 1996. C/EBP activators are
required for HIV-1 replication and proviral induction in monocytic cell lines.
Immunity 5:91.
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
1. Fauci, A. S. 1996. Host factors and the pathogenesis of HIV-induced disease.
Nature 384:529.
2. McArthur, J. C., D. R. Hoover, H. Bacellar, E. N. Miller, B. A. Cohen,
J. T. Becker, N. M. Graham, J. H. McArthur, O. A. Selnes, L. P. Jacobson, et al.
1993. Dementia in AIDS patients: incidence and risk factors: Multicenter AIDS
Cohort Study. Neurology 43:2245.
3. Kolson, D. L., and F. Gonzalez-Scarano. 2000. HIV and HIV dementia. J. Clin.
Invest. 106:11.
4. Fischer-Smith, T., S. Croul, A. E. Sverstiuk, C. Capini, D. L’Heureux,
E. G. Regulier, M. W. Richardson, S. Amini, S. Morgello, K. Khalili, et al. 2001.
CNS invasion by CD14⫹/CD16⫹ peripheral blood-derived monocytes in HIV
dementia: perivascular accumulation and reservoir of HIV infection. J. Neurovirol. 7:528.
5. Cosenza, M., M. Zhao, Q. Si, and S. Lee. 2002. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 encephalitis. Brain Pathol. 12:442.
6. Krebs, F. C., H. Ross, J. McAllister, and B. Wigdahl. 2000. HIV-1-associated
central nervous system dysfunction. Adv. Pharmacol. 49:315.
7. Major, E. O., D. Rausch, C. Marra, and D. Clifford. 2000. HIV-associated dementia. Science 288:440.
8. Koenig, S., H. E. Gendelman, J. M. Orenstein, M. C. Dal Canto,
G. M. Pezeshkpour, M. Yungbluth, F. Janotta, A. Aksamit, M. A. Martin, and
A. S. Fauci. 1986. Detection of AIDS virus in macrophages in brain tissue from
AIDS patients with encephalopathy. Science 233:1089.
9. Glass, J. D., H. Fedor, S. L. Wesselingh, and J. C. McArthur. 1995. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 38:755.
10. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, I. K. Hewlett, K. Yamada, and
S. Dhawan. 1996. HIV-1-Tat modulates the function of monocytes and alters
their interactions with microvessel endothelial cells. J. Immunol. 156:1638.
11. Esser, R., H. von Briesen, M. Brugger, M. Ceska, W. Glienke, S. Muller,
A. Rehm, W. H. Rubsamen, and R. Andreesen. 1991. Secretory repertoire of
HIV-infected human monocytes/macrophages. Pathobiology 59:219.
12. Gartner, S. 2000. HIV infection and dementia. Science 299:440.
13. Kaul, M., G. Garden, and S. Lipton. 2001. Pathways to neuronal injury and
apoptosis in HIV-associated dementia. Nature 410:988.
14. Poli, G., P. Bressler, A. Kinter, E. Duh, W. C. Timmer, A. Rabson,
J. S. Justement, S. Stanley, and A. S. Fauci. 1990. Interleukin 6 induces human
immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor ␣ by transcriptional and post-transcriptional
mechanisms. J. Exp. Med. 172:151.
15. Poli, G., A. Kinter, J. S. Justement, J. H. Kehrl, P. Bressler, S. Stanley, and
A. S. Fauci. 1990. Tumor necrosis factor ␣ functions in an autocrine manner in
the induction of human immunodeficiency virus expression. Proc. Natl. Acad.
Sci. USA 87:782.
16. Poli, G., A. L. Kinter, and A. S. Fauci. 1994. Interleukin 1 induces expression of
the human immunodeficiency virus alone and in synergy with interleukin 6 in
chronically infected U1 cells: inhibition of inductive effects by the interleukin 1
receptor antagonist. Proc. Natl. Acad. Sci. USA 91:108.
17. Koyanagi, Y., W. O’Brien, J. Q. Zhao, D. W. Golde, and J. C. Gasson, and
I. S. Chen. 1988. Cytokines alter HIV-1 from primary mononuclear phagocytes.
Science 241:1673.
18. Osborn, L., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor ␣ and
interleukin 1 stimulate the human immunodeficiency virus enhancer by activation
of the nuclear factor ␬B. Proc. Natl. Acad. Sci. USA 86:2336.
19. Folkes, T. M., J. Justement, A. Kinter, C. A. Dinarello, and A. S. Fauci. 1987.
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell
line. Science 238:800.
20. Correll, P., A. Morrison, and M. Lutz. 2004. Receptor tyrosine kinases and the
regulation of macrophage activation. J. Leukocyte Biol. 75:731.
21. Liu, Q., K. Fruit, J. Ward, and P. Correll. 1999. Negative regulation of macrophage activation in response to IFN-␥ and LPS by the STK/RON receptor tyrosine kinase. J. Immunol. 163:6606.
22. Chen, Y.-Q., J. H. Fisher, and M.-H. Wang. 1998. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression
by murine peritoneal exudates macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J. Immunol. 161:4950.
6871
6872
RON RECEPTOR TYROSINE KINASE INHIBITS HIV-1 TRANSCRIPTION
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
site mediates signaling and transformation by the hepatocyte growth factor/scatter
factor receptor family. Cell 77:261.
Iwama, A., N. Yamaguchi, and T. Suda. 1996. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking
site conserved among the HGF receptor family. EMBO J. 15:5866.
Cook, J. A., A. August, and A. J. Henderson. 2002. Recruitment of phosphatidylinositol 3-kinase to CD28 inhibits HIV transcription by a Tat-dependent
mechanism. J. Immunol. 169:254.
Longati, P., A. Bardelli, C. Ponzetto, L. Naldini, and P. Comoglio. 1994. Tyrosines 1234 –1235 are critical for activation of the tyrosine kinase encoded by
the MET proto-oncogene (HGF receptor). Oncogene 9:49.
Yang, X., Y. Chen, and D. Gabuzda. 1999. ERK MAP kinase links cytokine
signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-␬B. J. Biol. Chem. 274:27981.
Bovolenta, C., L. Camorali, A. L. Lorini, S. Ghezzi, E. Vicenzi, A. Lazzarin, and
G. Poli. 1999. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 94:4202.
Cartier, C., M. Deckert, C. Grangeasse, R. Trauger, F. Jensen, A. Bernard,
A. Cozzone, C. Desgranges, and V. Boyer. 1997. Association of ERK2 mitogenactivated protein kinase with human immunodeficiency virus particles. J. Virol.
71:4832.
Jacque, J., A. Mann, H. Enslen, N. Sharova, B. Brichacek, R. Davis, and
M. Stevenson. 1998. Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. EMBO J. 17:2607.
Muraoka, R. S., W. Y. Sun, M. C. Colbert, S. E. Waltz, D. P. Witte, J. L. Degen,
and S. J. Friezner Degen. 1999. The Ron/STK receptor tyrosine kinase is essential
for peri-implantation development in the mouse. J. Clin. Invest. 103:1277.
Schmidt, O., E. Doxakis, and A. M. Davies. 2002. Macrophage-stimulating protein is a neurotrophic factor for embryonic chicken hypoglossal motoneurons.
Eur. J. Neurosci. 15:101.
Stella, M. C., A. Vercelli, M. Repici, A. Follenzi, and P. M. Comoglio. 2001.
Macrophage stimulating protein is a novel neurotrophic factor. Mol. Biol. Cell
12:1341.
Blagoveshchenskaya, A., L. Thomas, S. Feliciangeli, C. Hung, and G. Thomas.
2002. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6
endocytic pathway. Cell 111:853.
De, S. K., C. N. Venkateshan, P. Seth, D. C. Gajdusek, and C. J. Gibbs. 1998.
Adenovirus-mediated human immunodeficiency virus-1 Nef expression in human
monocytes/macrophages and effect of Nef on downmodulation of Fc␥ receptors
and expression of monokines. Blood 91:2108.
Swigut, T., N. Shohdy, and J. Skowronski. 2001. Mechanism for down-regulation
of CD28 by Nef. EMBO J. 20:1593.
Noonan, D., and A. Albini. 2000. From the outside in: extracellular activities of
HIV Tat. Adv. Pharmacol. 48:229.
Wang, M.-H., H.-L. Fung, and Y.-Q. Chen. 2000. Regulation of the RON receptor tyrosine kinase expression in macrophages: blocking the RON gene transcription by endotoxin-induced nitric oxide. J. Immunol. 164:3815.
Downloaded from http://www.jimmunol.org/ by guest on June 16, 2017
50. Tesmer, V. M., A. Rajadhyaksha, J. Babin, and M. Bina. 1993. NF-IL6-mediated
transcriptional activation of the long terminal repeat of the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:7298.
51. Yang, Y., V. M. Tesmer, and M. Bina. 2002. Regulation of HIV-1 transcription
in activated monocyte macrophages. Virology 299:256.
52. Gaudino, G., V. Avantaggiato, A. Follenzi, D. Acampora, A. Simeone, and
P. M. Comoglio. 1995. The proto-oncogene RON is involved in development of
epithelial, bone and neuro-endocrine tissues. Oncogene 11:2627.
53. Forgie, A., S. Wyatt, P. H. Correll, and A. M. Davies. 2003. Macrophage stimulating protein is a target-derived neurotrophic factor for developing sensory and
sympathetic neurons. Development 130:995.
54. Janabi, N., S. Peudenier, B. Heron, K. Ng, and M. Tardieu. 1995. Establishment
of human microglia cell lines after transfection of primary cultures of embryonic
microglia cells with SV40 large T antigen. Neurosci. Lett. 195:105.
55. Ponten, J., and E. H. Macintyre. 1968. Long term culture of normal and neoplastic human glia. Acta Pathol. Microbiol. Scand. 74:465.
56. Anderson, C., and D. Mosser. 2002. Cutting edge: biasing immune responses by
directing antigen to macrophage Fc␥ receptors. J. Immunol. 168:3697.
57. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol.
3:23.
58. Lemke, G., and Q. Lu. 2003. Macrophage regulation by Tyro 3 family receptors.
Curr. Opin. Immunol. 15:31.
59. Fadok, V., D. Bratton, D. Rose, A. Pearson, R. Ezekewitz, and P. Henson. 2000.
A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature
405:85.
60. Kent, S. J., G. Stent, S. Sonza, S. D. Hunter, and S. M. Crowe. 1994. HIV-1
infection of monocyte-derived macrophages reduces Fc and complement receptor
expression. Clin. Exp. Immunol. 95:450.
61. Kedzierska, K., P. Ellery, J. Mak, S. R. Lewin, S. M. Crowe, and
I. A. Jaworowsk. 2002. HIV-1 down-modulates ␥ signaling chain of Fc␥R in
human macrophages: a possible mechanism for inhibition of phagocytosis. J. Immunol. 168:2895.
62. Wang, M. H., G. W. Cox, T. Yoshimura, L. A. Sheffler, A. Skeel, and
E. J. Leonard. 1994. Macrophage-stimulating protein inhibits induction of nitric
oxide production by endotoxin- or cytokine-stimulated mouse macrophages.
J. Biol. Chem. 269:14027.
63. Griffin, G., K. Leung, T. Folks, S. Kunkel, and G. Nabel. 1991. Induction of
NF-␬B during monocyte differentiation is associated with activation of HIV-gene
expression. Res. Virol. 142:233.
64. Pazin, M., P. Sheridan, K. Cannon, Z. Cao, J. Keck, J. Kadonaga, and K. Jones.
1996. NF-␬B-mediated chromatin reconfiguration and transcriptional activation
of the HIV-1 enhancer in vitro. Genes Dev. 10:37.
65. Widak, P., R. Gaynor, and W. Garrard. 1997. In vitro chromatin assembly of the
HIV-1 promoter. J. Biol. Chem. 272:17654.
66. Ponzetto, C., A. Bardelli, Z. Zhen, F. Maina, P. dalla Zonca, S. Giordano,
A. Graziani, G. Panayotou, and P. M. Comoglio. 1994. A multifunctional docking